New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 3, #12, April 1998
State-of-the-Art in the Management of Cancer

Prostate Cancer-PART II
Diagnosis, Staging, Prognosis, Screening, and Novel Molecular Markers

Diagnostic and Screening Tests

  • Prostate Specific Antigen (PSA)
  • Prostate Acid Phosphatase (PAP)
  • ProstaScint
  • Angiogenesis
  • Cytokine Overexpression

Novel Molecular Markers

Markers Associated with Familial/Hereditary Prostate Cancer

  • Androgen receptor
  • BRCA1 or BRCA2
  • Hereditary prostate cancer 1 (HPCA1)

Other Markers

  • Insulin-like growth factor-I (IGF-I)
  • Nuclear matrix proteins (NMPs)
  • P53
  • Prostate stem cell antigen (PSCA)
  • Prostate specific membrane antigen (PSMA)

Meeting Coverage

Report from the Sixth International Conference on Gene Therapy of Cancer
Sponsored by the Sidney Kimmel Cancer Center
Nov 19-22, 1997, San Diego, CA

Apoptosis and Gene Therapy

P53

Introgen Therapeutics

  • Phase I clinical trials in head and neck cancer
  • Phase I studies of INGN 201 for treating non-small cell lung cancer
  • Ovarian cancer
  • Preclinical studies of p53 replacement gene therapy for pancreatic cancer
  • Tumor regression in vivo following p53 combination therapy

Canji (Schering-Plough)

  • Phase I clinical trials of intra-hepatic SCH 58500
  • Adenovirus-mediated p53 gene therapy synergizes with paclitaxel

Onyx Pharmaceuticals

  • Phase I clinical trial of ONYX-015
  • Preclinical studies with ONYX-015 in combination with chemotherapy

Cell Cycle-based Gene Therapy

  • HepaVec
  • Canji

Bcl-2

JNK/SAPK Pathway

  • Isis Pharmaceuticals

Other Gene Therapy Approaches

  • Inhibition of Nude Mice Xenografts Using Growth Inhibitory Gene Mda-7
  • Anti-Papillomavirus Ribozymes
  • Anti-ras and Anti-raf Approaches
  • Apoptin
  • Interleukin-1b Converting Enzyme (ICE)

Suicide Gene Therapy Strategies.

Target Selectivity

Pre-emptive Suicide Gene Strategies

Herpes Simplex Virus Thymidine Kinase (HSV-tk) Gene Combined with the Prodrug Ganciclovir (GCV)

  • Phase II clinical trials of GLI 328 HSV-Tk gene therapy in recurrent glioblastoma
  • A series of phase I clinical trials using adenoviral-based gene therapy for malignant mesothelioma with concomitant immunosuppression
  • Noninvasive imaging of adenoviral-mediated HSV-tk gene transfer and expression

Other Prodrug Activating Gene Therapy

  • Mutant HSV-1 tk combined with acyclovir
  • Other prodrug-activating gene combinations
  • New enzyme/prodrug combinations for use in gene-directed enzyme prodrug therapy (GDEPT)

The Bystander Effect

  • Evaluation of Adenovirus p53-mediated "Bystander Effect" In Vivo
  • Bystander Effect in HSV-Tk Suicide Gene Therapy.

Improving Delivery Approaches

  • Enhancing Nonviral Delivery
  • Vaccinia Virus Vectors
  • Tumor-specific Ligand-liposome Gene Delivery

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887